Moderna 与 Merck 的 AI 辅助个体化 mRNA 癌症疗法在涉及 1,137 名患者的 Phase 3 试验中取得成功,作者称这是该疗法首次在 Phase 3 试验中成功。
内容给出 AI 筛选肿瘤新抗原并定制 mRNA 疗法的流程,以及 Phase 2 与 Phase 3 的对照数据,便于了解 AI 在个体化癌症治疗中的位置。
This is freaking huge: For the first time, a AI-assisted personalized mRNA cancer treatment has succeeded in a Phase 3 trial.
Moderna and Merck sequence each patient’s tumor and compare it with their healthy DNA. AI then helps identify which of the tumor’s mutations are most likely to trigger an immune response.
From those targets, Moderna produces an individual mRNA treatment encoding up to 34 neoantigens, The earlier Phase 2 trial followed patients with surgically removed high-risk melanoma for five years:
- 68.8% remained cancer-free, compared with 49.1% on Keytruda alone
- 49% lower risk of recurrence or death
- 59% lower risk of distant metastasis or death
Now the much larger Phase 3 trial involving 1,137 patients has also succeeded.
Absolutely incredible. Dario was right: cancer will be cured in just a few years!
来源:@kimmonismus · x.com